Amneal's record quarter and Kashiv biosimilars deal offset by weak growth warnings
Record Q2 results and raised guidance Amneal reported record Q2 revenue of $796 million, up 10% year-over-year, and raised full-year guidance for the second time in 2026. Adjusted EPS rose 20% and margins improved, showing the core business is growing and more profitable than expected, which supports a higher stock price.
This is the strongest new positive fundamental event, directly lifting earnings expectations and investor confidence.
Kashiv acquisition opens biosimilars market Amneal completed its purchase of Kashiv BioSciences, giving it full control over biosimilar development and manufacturing. Biosimilars are copycat versions of expensive biologic drugs, a market that could exceed $300 billion as patents expire. This adds a new long-term growth engine beyond generics.
The deal is a new strategic move that expands Amneal's addressable market and future revenue potential.
FDA approval expands iohexol contrast agent line Amneal won FDA approval for additional strengths and vial sizes of iohexol injection, a generic contrast dye used in medical scans. The expanded lineup now covers most of a $706 million U.S. market, with launch planned for Q3 2026. This adds near-term product revenue.
New regulatory approval directly enables additional sales and market share in an existing product category.
Weak long-term growth and low returns raise caution Analysts flagged Amneal's projected revenue growth of just 2.6% over the next year, down sharply from 8.7% historically. Free cash flow margin has been flat at 8.9% for five years, and return on invested capital averages only 4.9%, below the cost of capital. This suggests limited upside and possible downside at current valuation.
This is the main counterweight, highlighting structural concerns that could cap the stock's gains despite recent positive news.